Wednesday, July 16, 2025 7/16/2025

Virginia-UCLA-Toronto Biomarker Characterization Center

Award Number: U2CCA271894
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/02/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2027

Group Awards By:

View Award Description

Virginia-UCLA-Toronto Biomarker Characterization Center - Project Summary The critical challenge in the clinical management of newly-diagnosed localized prostate cancer remains distinguishing indolent from aggressive and life-threatening cancers. Biomarkers are urgently needed to identify those patients who harbor aggressive disease and will derive benefit from definitive treatment. We therefore, propose to apply complimentary proteogenomic-based discovery approaches to identify and then validate molecular features in prostate proximal fluids and tumor tissues that will be utilized in accurate early detection of aggressive forms of prostate cancer and improve disease risk stratification. The intended use of these biomarkers will be the early identification of men at risk for grade progression and improved risk- stratification for them. We have three biomarker development laboratory aims: 1) Validate our existing urine-based biomarkers for grade progression in a ProBE-compliant study selected from our own cohorts and the EDRN GU upgrading study. 2) Develop and validate urine and tissue-based biomarkers for the risk-stratification of MRI “invisible” high-grade lesions. 3) Develop and validate biomarkers to sub-stratify risk associated with deleterious germline BRCA2 variants. Our biomarker reference laboratory will develop and validate targeted clinically robust assays for multi-protein biomarkers panels. We will also develop decision algorithms that are cross-referenced for statistical rigor and benchmarked for optimal clinical performance. In addition to these BCC activities, we will develop robust PRM-MS assays and statistically rigorous decision tools for other EDRN BCCs and CVCs. Taken together, our EDRN biomarker characterization center will be a core part of the the EDRN ecosystem. We will continue to actively participate in trans-Network activities, and to share patient cohorts, protocols, datasets and analysis approaches and expertise. We will supplement these activities by focusing on promoting the growth of new and diverse talent in biomarker development through fostering junior investigator involvement across the full spectrum of biomarker development.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	OLD DOMINION UNIVERSITY	735 FAIRFAX AVE STE 909	NORFOLK	VA	23507	NORFOLK CITY	USA	Cancer Detection and Diagnosis Research	001	2	3/3/2025	NON-COMPETING CONTINUATION	-$569,990
2025	2023	OLD DOMINION UNIVERSITY	HAMPTON BLVD	NORFOLK	VA	23529	NORFOLK CITY	USA	Cancer Detection and Diagnosis Research	002	3	3/3/2025	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$578,070
2025	2022	OLD DOMINION UNIVERSITY	735 FAIRFAX AVE STE 909	NORFOLK	VA	23507	NORFOLK CITY	USA	Cancer Detection and Diagnosis Research	000	1	3/3/2025	NEW	-$8,080
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $801,603 )
2024	2024	OLD DOMINION UNIVERSITY	HAMPTON BLVD	NORFOLK	VA	23529	NORFOLK CITY	USA	Cancer Detection and Diagnosis Research	002	4	9/11/2024	NON-COMPETING CONTINUATION	$801,603
2024	2023	OLD DOMINION UNIVERSITY	HAMPTON BLVD	NORFOLK	VA	23529	NORFOLK CITY	USA	Cancer Detection and Diagnosis Research	001	3	9/9/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$257,353
2024	2023	EASTERN VIRGINIA MEDICAL SCHOOL	735 FAIRFAX AVE STE 909C	NORFOLK	VA	23507	NORFOLK CITY	USA	Cancer Detection and Diagnosis Research	000	2	9/9/2024	NON-COMPETING CONTINUATION	-$257,353
														Subtotal = $801,603

Issue Date FY: 2023 ( Subtotal = $854,554 )
2023	2023	EASTERN VIRGINIA MEDICAL SCHOOL	735 FAIRFAX AVE STE 909C	NORFOLK	VA	23507	NORFOLK CITY	USA	Cancer Detection and Diagnosis Research	001	2	8/21/2023	NON-COMPETING CONTINUATION	$827,343
2023	2022	EASTERN VIRGINIA MEDICAL SCHOOL	735 FAIRFAX AVE STE 909C	NORFOLK	VA	23507	NORFOLK CITY	USA	Cancer Detection and Diagnosis Research	000	1	4/18/2023	NEW	$27,211
														Subtotal = $854,554

Issue Date FY: 2022 ( Subtotal = $636,916 )
2022	2022	EASTERN VIRGINIA MEDICAL SCHOOL	735 FAIRFAX AVE STE 909C	NORFOLK	VA	23507	NORFOLK CITY	USA	Cancer Detection and Diagnosis Research	000	1	9/2/2022	NEW	$636,916
														Subtotal = $636,916

Grand Total All Awards = $2,293,073

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Virginia-UCLA-Toronto Biomarker Characterization Center

Award Number: U2CCA271894

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/02/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer